The aim of this paper was to find a link between Peyronie's Disease (PD) and bioavailable (bT)/free testosterone (fT) blood levels.
Subjects with no erectile dysfunction were prospectively studied with respect to 3 parameters: differences in bT/fT between 106 PD patients and 99 healthy controls; differences in plaque area, penile curvature and pain between 54 PD patients with low bT/fT and 52 PD patients with normal bT/fT, and differences in intraplaque verapamil efficacy between 20 hypogonadal PD patients supplemented with testosterone and 23 hypogonadal PD patients administered a placebo. Medical history, objective examination, dynamic duplex scanning of the penis, both before and eight months after the end of the therapy (= i.e. the study period), were used to assess PD. Testosterone supplementation was carried out with testosterone buccal adhesive patches 2 x 30 mg/day (Striant 30 mg; Sanofi-Aventis Pharma, Paris, France) for the entire study period.
BT and fT were significantly lower in PD patients than in control patients. The plaque area was significantly higher in PD patients with low bT/fT than in patients with normal bT/fT. No significant difference emerged when pain or penile deformity were examined. Plaque area and penile curvature improved to a greater extent when intraplaque verapamil injections were associated with testosterone administration than when associated with a placebo.
Men with PD have lower bT/fT than healthy controls. In these patients, supplementation with testosterone improves the efficacy of intraplaque verapamil. Plaque area and penile curvature are more severe in hypogonadal PD.
Cavallini G, Biagiotti G, Lo Giudice C. Are you the author?
Reference: J Androl. 2011 Jun 30. Epub ahead of print.